NASDAQ:NVIVInvivo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Invivo Therapeutics Holdings Corp Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.50 -0.06 (-3.85 %) (As of 05/26/2020 04:00 PM ET) Add Compare Share Today's Range$1.44Now: $1.50▼$1.5550-Day Range$1.32MA: $1.48▼$1.8052-Week Range$1.09Now: $1.50▼$41.10Volume404,876 shsAverage Volume563,114 shsMarket Capitalization$7.28 millionP/E RatioN/ADividend YieldN/ABeta1.6 ProfileAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media InVivo Therapeutics Holdings Corp., a research and clinical-stage biomaterials and biotechnology company, engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries. It is developing Neuro-Spinal Scaffold implant, an investigational bioresorbable polymer scaffold for implantation at the site of injury within a spinal cord. InVivo Therapeutics Holdings Corp. has research collaboration with the Q Therapeutics, Inc. for the evaluation of the combination of PLGA-PLL based Neuro-Spinal Scaffold with adult neural progenitor cells, including those from induced pluripotent stem cells. The company was founded in 2005 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Invivo Therapeutics. Previous Next 2.8 Community Rank Outperform VotesInvivo Therapeutics has received 227 “outperform” votes. (Add your “outperform” vote.)Underperform VotesInvivo Therapeutics has received 185 “underperform” votes. (Add your “underperform” vote.)Community SentimentInvivo Therapeutics has received 55.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Invivo Therapeutics and other stocks. Vote “Outperform” if you believe NVIV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe NVIV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldInvivo Therapeutics does not currently pay a dividend.Dividend GrowthInvivo Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Invivo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.50% of the stock of Invivo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 2.81% of the stock of Invivo Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Book Value per Share RatioInvivo Therapeutics has a P/B Ratio of 0.76. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.69 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NVIV Previous Symbol CUSIPN/A CIK1292519 Webwww.invivotherapeutics.com Phone617-863-5500Debt Debt-to-Equity Ratio0.10 Current Ratio5.33 Quick Ratio5.33Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.97 per share Price / Book0.76Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-11,830,000.00 Net MarginsN/A Return on Equity-138.75% Return on Assets-99.84%Miscellaneous Employees6 Outstanding Shares4,850,000Market Cap$7.28 million Next Earnings Date8/11/2020 (Estimated) OptionableNot Optionable NASDAQ:NVIV Rates by TradingView Receive NVIV News and Ratings via Email Sign-up to receive the latest news and ratings for NVIV and its competitors with MarketBeat's FREE daily newsletter. Invivo Therapeutics (NASDAQ:NVIV) Frequently Asked Questions How has Invivo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Invivo Therapeutics' stock was trading at $1.60 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVIV shares have decreased by 6.3% and is now trading at $1.50. View which stocks have been most impacted by Coronavirus. When is Invivo Therapeutics' next earnings date? Invivo Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Invivo Therapeutics. How were Invivo Therapeutics' earnings last quarter? Invivo Therapeutics Holdings Corp (NASDAQ:NVIV) issued its quarterly earnings results on Wednesday, May, 13th. The biotechnology company reported ($2.47) earnings per share (EPS) for the quarter. View Invivo Therapeutics' earnings history. When did Invivo Therapeutics' stock split? How did Invivo Therapeutics' stock split work? Shares of Invivo Therapeutics reverse split on Wednesday, February 12th 2020. The 1-30 reverse split was announced on Monday, February 3rd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 11th 2020. An investor that had 100 shares of Invivo Therapeutics stock prior to the reverse split would have 3 shares after the split. Has Invivo Therapeutics been receiving favorable news coverage? Press coverage about NVIV stock has been trending very positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Invivo Therapeutics earned a daily sentiment score of 4.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutInvivo Therapeutics. Are investors shorting Invivo Therapeutics? Invivo Therapeutics saw a increase in short interest in May. As of May 15th, there was short interest totaling 46,200 shares, an increase of 82.6% from the April 30th total of 25,300 shares. Based on an average daily trading volume, of 604,600 shares, the short-interest ratio is presently 0.1 days. Currently, 1.0% of the shares of the company are sold short. View Invivo Therapeutics' Current Options Chain. Who are some of Invivo Therapeutics' key competitors? Some companies that are related to Invivo Therapeutics include Neovasc (NVCN), Invo Bioscience (IVOB), DarioHealth (DRIO), Biostage (BSTG), Atossa Genetics (ATOS), Interpace Diagnostics Group (IDXG), Titan Medical (TMDI), Endologix (ELGX), Avinger (AVGR), Dynatronics (DYNT), Sintx Technologies (SINT), Lianluo Smart (LLIT), Encision (ECIA), PlusTherapeuticsInc . (PSTV) and Hancock Jaffe Laboratories (HJLI). View all competitors. What other stocks do shareholders of Invivo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Invivo Therapeutics investors own include Anavex Life Sciences (AVXL), Gilead Sciences (GILD), iShares US Preferred Stock ETF (PFF), Verastem (VSTM), Flexion Therapeutics (FLXN), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Apollo Investment (AINV), Inovio Pharmaceuticals (INO) and Ophthotech (OPHT). Who are Invivo Therapeutics' key executives? Invivo Therapeutics' management team includes the following people: Dr. Richard M. Toselli, Pres, CEO, Chief Medical Officer & Director (Age 61)Dr. Robert S. Langer Jr., Co-Founder & Member of Scientific Advisory Board (Age 70)Dr. Joseph Philip Vacanti, Co-Founder (Age 70)Mr. Richard C. Christopher, Chief Financial Officer (Age 49)Mr. William D'Agostino PE, Sr. VP of Operations What is Invivo Therapeutics' stock symbol? Invivo Therapeutics trades on the NASDAQ under the ticker symbol "NVIV." Who are Invivo Therapeutics' major shareholders? Invivo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (0.67%), Wedbush Securities Inc. (4.82%) and Perkins Capital Management Inc. (3.53%). View institutional ownership trends for Invivo Therapeutics. Which major investors are selling Invivo Therapeutics stock? NVIV stock was sold by a variety of institutional investors in the last quarter, including Perkins Capital Management Inc.. View insider buying and selling activity for Invivo Therapeutics. Which major investors are buying Invivo Therapeutics stock? NVIV stock was purchased by a variety of institutional investors in the last quarter, including Sabby Management LLC, and Wedbush Securities Inc.. View insider buying and selling activity for Invivo Therapeutics. How do I buy shares of Invivo Therapeutics? Shares of NVIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Invivo Therapeutics' stock price today? One share of NVIV stock can currently be purchased for approximately $1.50. How big of a company is Invivo Therapeutics? Invivo Therapeutics has a market capitalization of $7.28 million. Invivo Therapeutics employs 6 workers across the globe. What is Invivo Therapeutics' official website? The official website for Invivo Therapeutics is www.invivotherapeutics.com. How can I contact Invivo Therapeutics? Invivo Therapeutics' mailing address is ONE KENDALL SQUARE SUITE B14402, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-863-5500 or via email at [email protected] This page was last updated on 5/27/2020 by MarketBeat.com Staff
